New agents with activity in recurrent epithelial ovarian cancer include the taxoids (paclitaxel and docetaxel), camptothecins (topotecan and irinotecan), gemcitabine, and oxaliplatin. In front-line therapy, the Gynecologic Oncology Group has shown that paclitaxel prolongs survival. In recurrent squamous carcinoma of the cervix, irinotecan has an objective response rate of 15%-24%. Both paclitaxel and docetaxel also show modest activity. Of these new agents, only paclitaxel has been evaluated in carcinoma of the endometrium, reporting a response rate of 35%.